Survey
on opinions of patients with bipolar disorder and their families shows
need for new drug treatments
Roughly 75 percent of patients with bipolar
disorder and their families see a need for new drug treatments, with
25 percent specifying a need for treatment that gives better control
of manic episodes without exacerbating depression, according to findings
released at the 15th annual European College of Neuropsychopharmacology
Congress. The report entitled "Bipolar Disorder: A Vision for
Better Understanding" represented survey results from 238 patients
and 233 family members in various European countries. The survey was
conducted from November 2001 to February 2002.
The impact of bipolar disorder on personal
life and employment was clearly shown by the survey results: Fully
60 percent of affected people considered suicide at least once.
Roughly 60 percent of affected people and nearly 75 percent of their
partners stated that the condition had led to relationship problems.
About 40 percent of patients and 10 percent of partners reported
losing a job or a job promotion because of bipolar disorder.
The difficulty in diagnosing and treating
bipolar disorder was also evident in survey findings. Roughly 75
percent of patients stated that they were originally misdiagnosed
after initial presentation of symptoms, often for durations up to
one year. Over 20 percent of respondents reported that they had
stopped drug treatment due to side effects.
Rodney Elgie, president of the Global Alliance
of Mental Illness Advocacy Networks, said "This report provides
further evidence of the need to bring bipolar disorder to the attention
of healthcare professionals and the wider community. I hope these
results will drive action in the form of timely recognition of symptoms,
faster diagnosis, and access to appropriate treatment."
John Cookson, M.D., a consultant psychiatrist
from Great Britain, said "This report underlines the need of
people with bipolar disorder to have access to effective treatments
that are not associated with some of the side effects common with
older therapies. Since this survey was conducted, a treatment option
has become available [in Europe] to help us meet these needs and
vastly improve the lives of our patients and those close to them,"
alluding to approval from the European Union for the use of an atypical
antipsychotic agent, olanzapine, for treatment of moderate to severe
manic episodes associated with bipolar disorder.
|